ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

PTGS2

prostaglandin-endoperoxide synthase 2 · also COX2 · Prostaglandin-endoperoxide synthase family

13 programs in company-led studies act on PTGS2, from 13 companies: 1 in phase 3, 12 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
AspirinruleBayerinhibitorphase 4844 runningPTGS1ChEMBL
AcetaminophenruleJohnson & Johnsoninhibitorphase 41363 runningFAAH, PTGS1, TRPV1ChEMBL
IbuprofenrulePfizerinhibitorphase 41132 runningPTGS1ChEMBL
MeloxicamruleBoehringer Ingelheiminhibitorphase 4672 running–ChEMBL
EtoricoxibruleOrganoninhibitorphase 4351 running–ChEMBL
SulfasalazineruleBristol-Myers Squibbinhibitorphase 471 runningALOX5, PTGS1ChEMBL
dexibuprofenruleAponia Laboratoriesinhibitorphase 461 runningPTGS1ChEMBL
BenzydamineruleAngelini Pharmainhibitorphase 441 runningPTGS1ChEMBL
DipyroneruleHypera Pharmainhibitorphase 441 runningPTGS1ChEMBL
CelecoxibruleViatrisinhibitorphase 4780 running–ChEMBL
dexketoprofenruleMenarini Groupinhibitorphase 480 runningPTGS1ChEMBL
PiroxicamruleTaisho Pharmaceuticalinhibitorphase 440 runningPTGS1ChEMBL
FlurbiprofenruleGlaxoSmithKlineinhibitorphase 3120 runningPTGS1ChEMBL

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.